Abstract
Athersys (Nasdaq: ATHX) is a biopharmaceutical company engaged in the discovery and development of novel therapies designed to treat significant unmet medical needs. The company is heavily focused on the regenerative medicine area, with multiple clinical and preclinical stage programs. The most advanced programs at the company are focused on the development of MultiStem®, a clinical stage allogeneic stem cell therapy that has demonstrated potential for treating a range of conditions and is believed to have widespread application in the field of regenerative medicine. The company has internal programs applying MultiStem across multiple therapeutic areas including cardiovascular, neurological, immune dysfunction and other disease areas, and partnered programs with Pfizer (applying MultiStem to treat inflammatory bowel disease) and Angiotech Pharmaceuticals (acute myocardial infarction). Athersys has a broad network of collaborative relationships with leading research and clinical institutions and is committed to developing a pipeline of novel ‘best-in-class’ medicines.
